Clinuvel Pharmaceuticals Ltd logo
CLVLF

Clinuvel Pharmaceuticals Ltd

Last Price US$8.45 Latest stored quote
Market Cap US$513.9m Company size context
7D Performance 0.00% Past 7 days
1Y Performance 22.46% Past 12 months
Model Rating Not rated Insufficient reported history for the model
Loading Mave Thesis research outlook

Dashboard Funda..tals Prediction Screener Map

Clinuvel Pharmaceuticals Ltd Overview

Industry: Biotechnology

Sector: Healthcare

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia. Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a s Read More

Reported Results

No latest earnings report cached yet

Run the EDGAR earnings refresh to load the latest company-filed earnings release, 10-Q, 10-K, or transcript exhibit for this ticker.

Prediction-grade evidence

Recent News

Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

No qualified company news in the last 14 days

No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.

Financial Statements

Company-reported SEC EDGAR facts organized into the three core statements.

SEC financial statements are temporarily unavailable.

Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

Clinuvel Pharmaceuticals Ltd logo

Clinuvel Pharmaceuticals Ltd

US$8.45

US$513.9m

0.00%

22.46%